Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, today announced that the abstract on the initial findings of the first two patients treated in its phase I/IIa WiNK trial have been accepted and will be presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021), which will take place 11th – 14th December 2021 in Atlanta, GA, USA. oNKord® is the company’s first-generation off-the-shelf allogeneic NK cell therapy under clinical development. Glycostem is furthermore developing a range of CAR-NK, combination therapy and TCR-NK products in-house.